Skip to main content
Equibles

UBS Group AG

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 1610520 ZURICH, V8
Back to TSHA Full portfolio

Position in TSHA

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$4,007,186
+$1,693,076 QoQ
Shares Held
588,427
+13.7% QoQ
Ownership
0.181%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#50
of 208 holders
Holding Since
Sep 2020
24 quarters on record
Voting authority Sole 97% Shared 0% None 3%

Common Shares in TSHA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,801 across 560 Biotechnology names. TSHA ranks #162 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in TSHA

Export CSV
24 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,007,186 588,427
2026-03-31 $2,314,110 517,698
2025-12-31 $2,106,736 383,043
2025-09-30 $2,090,693 639,356
2025-06-30 $603,462 261,239
2025-03-31 $581,202 418,132
2024-12-31 $729,014 421,396
2024-09-30 $184,921 92,001
2024-06-30 $125,616 56,079
2024-03-31 $543,244 189,284
2023-12-31 $6,978 3,943
2023-09-30 $1,738 550
2023-06-30 $5,227 7,909
2023-03-31 $2,832 3,550
2022-12-31 $456,144 201,834
2022-09-30 $12,104 6,272
2022-06-30 $351,763 94,560
2022-03-31 $443,229 67,980
2021-12-31 $594,568 51,036
2021-09-30 $621,591 33,383
2021-06-30 $112,360 5,300
2021-03-31 $735,083 36,211
2020-12-31 $948,778 35,749
2020-09-30 $246,400 11,000